300 related articles for article (PubMed ID: 11054062)
1. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
2. Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance.
Den Boer ML; Kapaun P; Pieters R; Kazemier KM; Janka-Schaub GE; Veerman AJ
Br J Haematol; 1999 Jun; 105(4):876-82. PubMed ID: 10554796
[TBL] [Abstract][Full Text] [Related]
3. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells.
Kaspers GJ; Pieters R; Van Zantwijk CH; Van Wering ER; Veerman AJ
Leuk Lymphoma; 1995 Nov; 19(5-6):407-16. PubMed ID: 8590840
[TBL] [Abstract][Full Text] [Related]
4. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
[TBL] [Abstract][Full Text] [Related]
5. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
Pieters R; den Boer ML; Durian M; Janka G; Schmiegelow K; Kaspers GJ; van Wering ER; Veerman AJ
Leukemia; 1998 Sep; 12(9):1344-8. PubMed ID: 9737681
[TBL] [Abstract][Full Text] [Related]
6. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.
Pieters R; Loonen AH; Huismans DR; Broekema GJ; Dirven MW; Heyenbrok MW; Hählen K; Veerman AJ
Blood; 1990 Dec; 76(11):2327-36. PubMed ID: 2257305
[TBL] [Abstract][Full Text] [Related]
7. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
8. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
Hongo T; Yamada S; Yajima S; Watanabe C; Fujii Y; Kawasaki H; Yazaki M; Hanada R; Horikoshi Y
Int J Hematol; 1999 Dec; 70(4):268-77. PubMed ID: 10643153
[TBL] [Abstract][Full Text] [Related]
9. The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol.
Mihal V; Hajduch M; Noskova V; Janostakova A; Safarova M; Orel M; Kouzmina G; Stary J; Blazek B; Pospisilova D
Bull Cancer; 2004 Apr; 91(4):E80-9. PubMed ID: 15562558
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party on Leukaemia in Adults.
Br J Haematol; 1974 Jul; 27(3):373-89. PubMed ID: 4607313
[No Abstract] [Full Text] [Related]
11. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.
Pieters R; Huismans DR; Loonen AH; Hählen K; van der Does-van den Berg A; van Wering ER; Veerman AJ
Lancet; 1991 Aug; 338(8764):399-403. PubMed ID: 1678081
[TBL] [Abstract][Full Text] [Related]
12. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
[TBL] [Abstract][Full Text] [Related]
13. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study.
Kaspers GJ; Smets LA; Pieters R; Van Zantwijk CH; Van Wering ER; Veerman AJ
Blood; 1995 Feb; 85(3):751-6. PubMed ID: 7833478
[TBL] [Abstract][Full Text] [Related]
14. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
Ramakers-van Woerden NL; Pieters R; Loonen AH; Hubeek I; van Drunen E; Beverloo HB; Slater RM; Harbott J; Seyfarth J; van Wering ER; Hählen K; Schmiegelow K; Janka-Schaub GE; Veerman AJ
Blood; 2000 Aug; 96(3):1094-9. PubMed ID: 10910927
[TBL] [Abstract][Full Text] [Related]
15. Treatment of high-risk acute lymphoblastic leukemia with protocols PETHEMA LAL 7/78 and LAL 17/84.
Ortega JJ; Javier G; Olivé T
An Esp Pediatr; 1988 Oct; 29 Suppl 34():72-83. PubMed ID: 3214043
[No Abstract] [Full Text] [Related]
16. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Parker C; Waters R; Leighton C; Hancock J; Sutton R; Moorman AV; Ancliff P; Morgan M; Masurekar A; Goulden N; Green N; Révész T; Darbyshire P; Love S; Saha V
Lancet; 2010 Dec; 376(9757):2009-17. PubMed ID: 21131038
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute nonlymphoid leukaemia with five different schedules including cytosine arabinoside and 6-thioguanine.
Mandelli F; Amadori S; De Luca AM; Deriu L; De Rossi G; Isacchi G; Mariani G; Monarca B; Papa G; Di Giovanni F
Haematologica; 1977 Apr; 62(2):167-84. PubMed ID: 406174
[No Abstract] [Full Text] [Related]
18. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
[TBL] [Abstract][Full Text] [Related]
19. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
Ramakers-van Woerden NL; Pieters R; Hoelzer D; Slater RM; den Boer ML; Loonen AH; Harbott J; Janka-Schaub GE; Ludwig WD; Ossenkoppele GJ; van Wering ER; Veerman AJ;
Med Pediatr Oncol; 2002 Jun; 38(6):379-86. PubMed ID: 11984797
[TBL] [Abstract][Full Text] [Related]
20. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia.
Pieters R; Kaspers GJ; van Wering ER; Huismans DR; Loonen AH; Hählen K; Veerman AJ
Leukemia; 1993 Mar; 7(3):392-7. PubMed ID: 8445945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
